<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364533</url>
  </required_header>
  <id_info>
    <org_study_id>CR011221</org_study_id>
    <secondary_id>R331333PAI3001</secondary_id>
    <secondary_id>KF5503/31</secondary_id>
    <nct_id>NCT00364533</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety</brief_title>
  <official_title>A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test in patients who have had hip replacement surgery the
      effectiveness (level of pain control) and the safety of 3 different dose levels of CG5503
      compared with placebo and with 10-mg oxycodone during the 72-hour double-blind period and to
      assess the safety of the drug for 9 days after patients completed the double blind period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing hip replacement often experience moderate to severe acute pain
      post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid
      analgesics. However, opioid therapy is commonly associated with side effects such as nausea,
      vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a
      newly synthesized drug also acts as a centrally acting pain reliever but has a dual mode of
      action. The aim of this study is to investigate the effectiveness (level of pain control) and
      safety (side effects) of 3 dose levels of CG5503, in an immediate release, (IR) formulation,
      compared with no drug (placebo) or one dose level of oxycodone (an opioid commonly used to
      treat post-surgical pain). This study is a randomized, double-blind (neither investigator nor
      patient will know which treatment was received), active- and placebo-controlled,
      parallel-group, multicenter study to evaluate the treatment of acute pain from hip
      replacement surgery. The study will include a blinded 72 hour in-patient phase immediately
      following hip replacement surgery, during which patients will be treated with either 50-,
      75-, or 100-mg CG5503 base IR, a placebo, or 10-mg oxycodone, and pain relief will be
      periodically assessed. Following this phase, patients wishing to continue treatment with
      CG5503 IR may enter an outpatient voluntary nonrandomized, open-label extension phase for 9
      days during which they will receive 50- or 100-mg CG5503 IR. Assessments of pain relief
      include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR)
      and patient global impression of change scale (PGIC). Safety evaluations include monitoring
      of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples
      will be collected for the determination of serum concentrations of CG5503 and oxycodone. The
      null hypothesis for the study is that efficacy results for all CG5503 IR dosage groups are
      equal to placebo based on the mean sum of pain intensity difference at 48 hours. The
      alternative study hypothesis is that at least 1 dose strength of CG5503 will be different
      from placebo in controlling pain at 48 hours. CG5503 base IR 50, or 75, or 100 mg, or
      oxycodone 10 mg, or placebo, 1 capsule taken by mouth every 4 to 6 hours during the 72 hour
      postsurgery phase of the study (one extra dose is allowed, if needed for pain); and CG5503,
      50 mg base capsules, 1 to 2 tablets taken by mouth every 4 to 6 hours for up to 9 days during
      the open label portion of the study. All doses of study treatment will be taken with
      approximately 120 mL of water with or with food.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference Over 48 Hours (SPID48)</measure>
    <time_frame>48 hours</time_frame>
    <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Pain Medication.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The SPID at 12, 24, and 72 Hours Relative to First Dose.</measure>
    <time_frame>3 days</time_frame>
    <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">367</enrollment>
  <condition>Arthroplasty</condition>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Fixed Dose Matching placebo for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapentadol IR (CG5503) Fixed Dose 50, 75, &amp; 100 mg BID for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 &amp; 100 mg BID for 9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol IR (CG5503)</intervention_name>
    <description>Fixed Dose 50, 75, &amp; 100 mg BID for 3 days</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fixed Dose Matching placebo for 3 days</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone HCL IR</intervention_name>
    <description>Fixed Dose 10 mg BID for 3 days</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol IR (CG5503)</intervention_name>
    <description>Flexible Dose q4-6 hr Tapentadol IR 50 &amp; 100 mg BID for 9 days</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo standard primary (first-time) one-sided total hip replacement
             surgery due to degenerative joint disease (arthritis), not due to some inflammatory
             process, (eg. infection)

          -  Baseline pain intensity &gt;= 4 on an 11-point (0 to 10) Pain Intensity rating scale,
             rated within 30 minutes before randomization

          -  Women must be postmenopausal, surgically sterile, or practicing or agree to practice
             an effective method of birth control throughout the study

        Exclusion Criteria:

          -  Patients will be excluded from the study if they have a history of seizure disorder or
             epilepsy

          -  history of malignancy within the past 2 years before starting the study

          -  history of alcohol or drug abuse

          -  evidence of active infections that may spread to other areas of the body

          -  clinical laboratory values reflecting moderate or severe kidney insufficiency

          -  currently treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic
             antidepressants, neuroleptics, or selective norepinephrine reuptake inhibitor (SNRI),
             (selective serotonin reuptake inhibitor [SSRI] treatments are allowed if taken for at
             least 30 days before the screening period of the study at an unchanged dose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sewickley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cadiz N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bor√•s</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>H√§ssleholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>√ñrebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Yarmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=61&amp;filename=CR011221_CSR.pdf</url>
    <description>A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>December 19, 2008</results_first_submitted>
  <results_first_submitted_qc>May 14, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2009</results_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthralgia</keyword>
  <keyword>Pain</keyword>
  <keyword>Pain Assessment</keyword>
  <keyword>Hip Replacement</keyword>
  <keyword>Tapentadol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tapentadol IR Fixed Dose 50 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Tapentadol IR Fixed Dose 75 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="P3">
          <title>Tapentadol IR Fixed Dose 100 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="P4">
          <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
          <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo Fixed Dose</title>
          <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject discharged from hospital</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Variations in drug compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapentadol IR Fixed Dose 50 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Tapentadol IR Fixed Dose 75 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Tapentadol IR Fixed Dose 100 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="B4">
          <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
          <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="B5">
          <title>Placebo Fixed Dose</title>
          <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="75"/>
            <count group_id="B6" value="365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="12.20"/>
                    <measurement group_id="B2" value="62.8" spread="9.24"/>
                    <measurement group_id="B3" value="63.3" spread="10.3"/>
                    <measurement group_id="B4" value="61.3" spread="12.39"/>
                    <measurement group_id="B5" value="64.0" spread="11.23"/>
                    <measurement group_id="B6" value="62.7" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Difference Over 48 Hours (SPID48)</title>
        <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
        <time_frame>48 hours</time_frame>
        <population>Because the Sponsor terminated the study, the planned sample size was not reached in any treatment group, therefore, only a brief summary of an exploratory analysis of the primary efficacy variable (SPID48) is presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR Fixed Dose 50 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Tapentadol IR Fixed Dose 75 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Tapentadol IR Fixed Dose 100 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
            <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo Fixed Dose</title>
            <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference Over 48 Hours (SPID48)</title>
          <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
          <population>Because the Sponsor terminated the study, the planned sample size was not reached in any treatment group, therefore, only a brief summary of an exploratory analysis of the primary efficacy variable (SPID48) is presented.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="123.89"/>
                    <measurement group_id="O2" value="54.4" spread="128.22"/>
                    <measurement group_id="O3" value="49.3" spread="136.92"/>
                    <measurement group_id="O4" value="57.6" spread="125.73"/>
                    <measurement group_id="O5" value="-18.6" spread="130.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The study was terminated and did not reach the planned sample size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference of SPID48</param_type>
            <param_value>91.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.77</ci_lower_limit>
            <ci_upper_limit>133.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The study was terminated and did not reach the planned sample size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference of SPID48</param_type>
            <param_value>81.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>38.66</ci_lower_limit>
            <ci_upper_limit>124.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The study was terminated and did not reach the planned sample size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference of SPID48</param_type>
            <param_value>81.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>39.21</ci_lower_limit>
            <ci_upper_limit>123.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The study was terminated and did not reach the planned sample size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference of SPID48</param_type>
            <param_value>82.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>38.96</ci_lower_limit>
            <ci_upper_limit>125.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Pain Medication.</title>
        <time_frame>3 days</time_frame>
        <population>Due to termination of trial, results were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR Fixed Dose 50 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Tapentadol IR Fixed Dose 75 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Tapentadol IR Fixed Dose 100 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
            <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo Fixed Dose</title>
            <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Pain Medication.</title>
          <population>Due to termination of trial, results were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The SPID at 12, 24, and 72 Hours Relative to First Dose.</title>
        <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
        <time_frame>3 days</time_frame>
        <population>Due to termination of trial, results were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR Fixed Dose 50 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Tapentadol IR Fixed Dose 75 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Tapentadol IR Fixed Dose 100 mg</title>
            <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
            <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo Fixed Dose</title>
            <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>The SPID at 12, 24, and 72 Hours Relative to First Dose.</title>
          <description>The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.</description>
          <population>Due to termination of trial, results were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were reported from the time a signed and dated informed consent was obtained throughout the follow-up phase of the study. Serious adverse events were collected for 30 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tapentadol IR Fixed Dose 50 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Tapentadol IR Fixed Dose 75 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="E3">
          <title>Tapentadol IR Fixed Dose 100 mg</title>
          <description>Tapentadol taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="E4">
          <title>Oxycodone HCL IR Fixed Dose 10 mg</title>
          <description>oxycodone 10mg taken by mouth every 4-6 hours for 3 days</description>
        </group>
        <group group_id="E5">
          <title>Placebo Fixed Dose</title>
          <description>Matching placebo taken by mouth every 4-6 hours for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hallucination, Visual</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A provision provides for 60 day prior review by sponsor extendable by 60 days to file a patent application and prior written consent of sponsor for disclosure of confidential information, if any.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sponsor terminated study, sample size not reached. The protocol section describes 4 study arms defining the treatment groups in the study design. The participant flow module describes the 5 treatment groups analyzed for the primary endpoint</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>609-730-6780</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

